COMMUNIQUÉS West-GlobeNewswire

VALNEVA : Déclaration d’actions et de droits de vote - Statut au 30 avril 2026 tenant compte d’informations intermédiaires au 5 mai 2026
05/05/2026
VALNEVA Déclaration d’actions et de droits de vote Statut au 30 avril 2026 tenant compte d’informations intermédiaires au 5 mai 2026 [...]
VALNEVA: Declaration of shares and voting rights - Status as of April 30, 2026 taking into account interim information as at May 5, 2026
05/05/2026
VALNEVA Declaration of shares and voting rights Status as of April 30, 2026 taking into account interim information as at May 5, 2026 [...]
IBA – ACQUISITION D’ACTIONS PROPRES
05/05/2026
Louvain-la-Neuve, Belgique, 5 mai 2026 – 18h30 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique [...]
IBA – ACQUISITION OF OWN SHARES
05/05/2026
Louvain-la-Neuve, Belgium, May 5 th , 2026 – 6:30 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) [...]
Smith+Nephew drives progress in chronic wound care with ALLEVYN™COMPLETE CARE Dressing and RENASYS™ EDGE tNPWT set to launch at EWMA 2026
05/05/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, continues to drive progress in chronic wound management with an industry-leading portfolio set to showcase at the upcoming European Wound [...]
Scilex Holding Company Announces Its Subsidiaries, ACEA Therapeutics, Inc. and ACEA Pharma, Inc., Entered into a Definitive Agreement with Phoenix Asia Holdings Limited
05/05/2026
PALO ALTO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non- [...]
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
05/05/2026
Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction [...]
Geron Plans to Present at Upcoming Investor Conferences
05/05/2026
FOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025
05/05/2026
Overall, studies show: OGM Can Resolve Previously Unresolved Rare Disease Cases OGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV Sensitivity and Genomic [...]
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
05/05/2026
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation at 2026 ASCO [...]
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
05/05/2026
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of [...]
Clene to Present at Upcoming May Conferences
05/05/2026
SALT LAKE CITY, May 05, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company [...]
PathAI and A.C.Camargo Cancer Center Announce Cooperation to Expand Digital Pathology with AI in Brazil via SUS
05/05/2026
Collaboration supports national digital pathology transformation initiatives and broadens access to AI-enabled oncological diagnostics BOSTON and SÃO PAULO, May 05, 2026 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI [...]
Transplants.org Launches as Centralized Education and Navigation Platform for Organ and Stem Cell Transplant Patients
05/05/2026
New nonprofit simplifies the transplant journey with clinician-backed guidance and transparent outcomes data WASHINGTON, May 05, 2026 (GLOBE NEWSWIRE) -- Transplants.org , a 501(c)(3) nonprofit organization, today [...]
Noom Names “Power of Habit” Author Charles Duhigg as Advisor, Releases New Research Linking GLP-1 Success to Habit Formation
05/05/2026
First-of-its-kind Noom Psychosocial GLP-1 Report finds more than 90% of GLP-1 users say medication helped them adopt healthier habits, with reported benefits extending beyond weight to quality of life, joy, and [...]
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
05/05/2026
MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034 (the “notes”) in a [...]
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
05/05/2026
FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current [...]
Microbot Medical®’s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
05/05/2026
Commercial adoption of the LIBERTY System by sites that participated in the clinical trial serves as a strong validation of the value it brings to everyday practice The Company will attend the Annual Global Embolization [...]
FibroBiologics CEO Issues Letter to Shareholders
05/05/2026
HOUSTON, May 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]

Pages